🔗 Share this article

An underground market for unapproved weight-loss drugs is propelled by social media fitness personalities and sellers on messaging platforms, according to recent findings.

Investigational Treatment Acquiring Popularity Online

The experimental drug, which remains in research studies, is being promoted by online personalities for its alleged fat-burning properties. Viewers are encouraged to message these profiles privately for source information, while also obtaining discount codes.

Thriving Commerce on Messaging Platforms

Separately, a robust market exists on Telegram, where communities with thousands of participants share “before and after” images, injection guides and claims of next-day UK delivery. Vendors market the substance there before directing customers to WhatsApp for transactions.

Understanding The Experimental Drug

Retatrutide is an investigational injectable developed by US drugmaker Eli Lilly. The drug affects three intestinal hormones – GLP-1, glucose-dependent insulinotropic polypeptide and glucagon. Early trials indicate it could assist individuals reduce up to 25% of their body weight. Referred to as the “triple G”, the drug is being hailed online as the successor to Ozempic.

Medical Experts Voice Worries

However, doctors and chemists have cautions that the sale of what remains an unapproved medication in the UK is worrisome and could result in individuals administering products of unknown origin.

Some professionals stated the popularity for retatrutide could be connected to the increasing price of licensed slimming products such as Mounjaro.

Legal Status and Implementation

Selling retatrutide on social media or Telegram is illegal in the UK, as it is an unlicensed drug that must not be marketed or supplied for human use under the British medical regulations.

Some content creators try to circumvent the regulations by referring to the substance as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a restricted substance, but advertising and supply can still violate pharmaceutical, marketing, and customer regulations, potentially leading to fines, prosecution or imprisonment.

Platform Response and Material Removal

According to the social media company, the platform has taken down problematic content and prohibited related keywords and query recommendations. The company stated it was committed to keeping the service safe and allocating resources in strengthening enforcement strategies.

Online Trading Operations

Research also discovered communities with up to 9,000 participants selling the experimental drug using the platform's built-in discovery tool, which operates like a public directory. Entering “retatrutide” instantly brings up groups with thousands of members, populated with photos of slimming results, positive testimonials and step-by-step instructions for preparing or injecting at home.

After minutes of joining one group, a seller posted contact information, where the majority of transactions take place. The seller sent an guidebook and guaranteed shipping within two days. When asked whether the substance was authentic, one seller said: “You can’t be sure.” Another provided a image of a supposed laboratory certificate. Not one inquired about body mass, medical conditions or past usage.

Item Information and Pricing

Inside these communities, posts display black plastic packages with postal service labels, stating to contain new batches. One communication stated: “It took eight of us to load them this morning.”

Customers can choose between dry substance containers, mixed at home with purified liquid, or ready-to-use pens usually priced at 160 pounds for 20 milligrams. When questioned how much time a injector should last, sellers give contradictory responses ranging from a few weeks to “depends on your body”.

Service Oversight and Security Measures

A representative for the messaging service said it actively monitored harmful content on its platform including content that encouraged the “misuse of controlled medications”. The company added that it eliminated “millions of pieces of harmful content each day”.

Healthcare Professional Warnings

“People are administering materials they can’t verify. Although the science behind this drug is valid, these digital versions may not include what they claim,” said Jason Murphy, the director of pharmacy at Chemist4U.

Dr Crystal Wyllie of Asda Online Doctor linked the increase in interest to current price rises for approved weight-loss medications such as Mounjaro. “With costs increasing, patients are using social media. But counterfeit injections are extremely risky. You can’t be certain what’s inside or whether the conditions they were made in was sterile,” she explained.

Her staff has previously seen individuals harmed by personal administration from unconfirmed suppliers. “We understand the disappointment, but buying from messaging apps or communication platforms is taking chances with your well-being,” said the doctor. “These materials could be impure or incorrectly dosed.”

Manufacturer Statement

A spokesperson from Eli Lilly stated retatrutide was in phase 3 research studies and had not been reviewed or approved by any regulatory agency anywhere in the world. “Consequently at this point no one can market [it] for human use,” they said, noting that any product “misleadingly claiming itself as a company investigational substance not yet approved … may expose users to possibly serious medical dangers”.